Sunitinib in refractory adrenocortical-carcinoma patients progressing after cytotoxic chemotherapy

Trial Profile

Sunitinib in refractory adrenocortical-carcinoma patients progressing after cytotoxic chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2013

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Adrenal cancer
  • Focus Therapeutic Use
  • Acronyms SIRAC
  • Most Recent Events

    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 01 Jun 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2007-001165-15).
    • 29 Aug 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004039).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top